SHARESIFT
Healthcare · data ~15-min delayed
403.04 USD -1.04%
| Price | 403.04 USD |
| Day change | -1.04% |
| Market cap | 217.90B |
| 52-week range | 288 – 447.03 |
| P/E (trailing) | 25.1 |
| Dividend yield | 2.50% |
| Payout ratio | 60.87% |
| Return on equity | 91.47% |
| Debt / equity | 490% |
| Beta | 0.43 |
| Sector | Healthcare |
| Value score | 29 / 100 |
Amgen Inc. (AMGN) scores 29/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 25.1 times trailing earnings and is classified in Healthcare. The dividend yield is 2.50%, paid from 61% of earnings. Return on equity is 91%, with debt at 490% of equity. On its filings it passes 7 of the nine Piotroski checks, which points to improving fundamentals. Its Altman Z-Score places it in the distress zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 7 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 1.73 — Distress zone. The model was built for manufacturers and scores lenders and capital-heavy businesses low by construction, so read this alongside the balance sheet.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.